Whole blood thrombin generation, platelet activation test and platelet-monocyte complex formation to predict hypercoagulability in patients with multiple myeloma

Whole blood thrombin generation, platelet activation test and platelet-monocyte complex formation to predict hypercoagulability in patients with multiple myeloma - Whole blood thrombin generation in patients with multiple myeloma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48375

Enrollment

Registered

2019-09-18

Start date

2020-01-20

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer of plasma cells Plasma cell myeloma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: For all participants (patients and controls): - Subjects of both gender - Age *18 - Written informed consent from the subject Patients with Multiple Myeloma: - Stable condition - Diagnosis of Multiple Myeloma - On active treatment with IMiD - Patient of the Meander Medical Center

Exclusion criteria

Exclusion criteria: For all participants (patients and controls): - Age below 18 - Known abnormalities of the coagulation system - Pregnancy - The use of anti-coagulant drugs (low molecular weight heparin (LMWH), vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs)) - Active infection, bleeding or other systemic diseases For controls (relatives: family or no-family): - Active malignancy - Personal history of bleeding or thrombotic events

Design outcomes

Primary

Measure	Time frame
Thrombin generation in whole blood, platelet activation and platelet-monocyte complex formation in patients with MM and in controls.	—

Secondary

Measure	Time frame
Not apllicable	—

Countries

Netherlands

Outcome results